Global Companion Diagnostics Market Assessment, By Product [Assay, Kits and Reagents, Software and Services], By Technology [Immunohistochemistry, Molecular Diagnostics, In-situ Hybridization, FISH, CISH, Real-time PCR, Gene Sequencing], By Application [Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, Gastric Cancer, Others], By End-user [Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Others], By Region, Opportunities and Forecast, 2017-2031F
Global companion diagnostics market is expected to experience rapid growth due to the growing demand for personalized medicine, growing prevalence of cancer cases, and technological advances in diagnostics and therapeutics.
Home>Industry Reports>Global Companion Diagnostics Market Assessment, Opportunities and Forecast, 2017-2031F
Global companion diagnostics market is projected to witness a CAGR of 10.23% during the forecast period 2024-2031F, growing from USD 7.1 billion in 2023 to USD 15.48 billion in 2031F. The companion diagnostics market is anticipated to grow under the influence of driving forces such as the growing demand for personalized medicine, the growing prevalence of cancer cases, and technological advances in diagnostics and therapeutics. As the demand for tailored medical facilities and personalized health solutions is rising, the market for companion diagnostics is expected to expand exponentially. The rising incidence of cancer cases boosts the demand for companion diagnostics products in the market to cater to the growing market demand for such products. Manufacturers and innovators are constantly involved in technical advances and utilization of several diagnostic techniques to develop high-quality products. In addition, regulatory agencies such as the United States FDA, CDSCO, and others are actively looking after the approvals of various developed products.
For instance, in December 2023, the United States FDA approved 173 products of companion diagnostic devices (in vitro and imaging tools). These products are mainly approved for the United States market to perform companion diagnostics tests.
Growing Demand for Personalized Medicine
Companion diagnostics methods play a pivotal role in providing personalized medicine. A companion diagnostic test crucially helps to unlock insights for a better understanding of the specific disease-causing genes, biomarkers, and other biomedical factors. Companion diagnostics enable healthcare providers to determine whether the patient responds to treatment or not, further ensuring the safety and efficacy of targeted therapies and simultaneous selection of the finest treatment for that patient without wasting time with trial-and-error method. The key players are also actively involved in driving innovation in companion diagnostics.
For instance, in September 2023, Cell Signaling Technology (CST), partnered with Leica Biosystems, to develop companion diagnostics assays by utilizing the CST’s extensive best-in-class antibodies portfolio. Leica is a global leader in providing the translation of pre-clinical research into companion diagnostics tests, further enabling pharmaceutical partners to develop and commercialize innovative diagnostic solutions. Cell Signaling Technology is a life science technology company and a leading provider of antibodies, kits, and services.
Growing Prevalence of Cancer
The growing prevalence of cancer cases is anticipated to significantly increase the demand for companion diagnostics methods and products. More than 90% of the market products addressing companion diagnostics are mainly indicated for various types of cancers, which further contributes to the larger market share of various types of cancer indications. Non-small Cell Lung Cancer (NSCLC), breast cancer, and colorectal cancer are some of the most common types of cancers for which the companion diagnostics products are FDA-approved and marketed. Manufacturers are actively involved in product development to cater to the market requirement to address the rising demand for such products as the prevalence of cancer is anticipated to increase drastically in the upcoming years.
For instance, in October 2023, Foundation Medicine Inc. announced that it had received United States FDA approval for FoundationOneCDx and FoundationOneLiquidCDx to be used as companion diagnostics with BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) of Pfizer for the treatment of adult metastatic non-small cell lung cancer (NSCLC) patients having BRAF V600E mutation.
Dominance of Real-time PCR Segment
The real-time PCR segment is anticipated to contribute to the largest market share in the market due to its speed, sensitivity, and accuracy in the detection and quantification of genetic material, which is crucial for detecting the therapeutic efficacy of drugs. Manufacturers are actively involved in product development and collaborative approaches to harness the resources at optimum levels to enhance market growth.
For instance, in October 2023, QIAGEN and Myriad Genetics announced a collaboration agreement for the development of companion diagnostic tests in the field of cancer. The collaboration aims to deliver curative products and services for pharmaceutical companies, further, enabling the development of commercial proprietary cancer diagnostics tests for the United States market, and subsequently providing companion diagnostic test kits for the global market. Through this collaboration, Myriad will leverage its robust commercial infrastructure for clinical sample testing and CLIA-certified, CAP-accredited lab platform, and assay development expertise while QIAGEN will contribute through its Sample to Insight solutions which include its PCR offerings, sample preparation, QIAseq next-generation sequencing technologies, and the QIAGEN Digital Insights portfolio of bioinformatics. The collaboration also focuses on the combined FDA and worldwide regulatory expertise of both organizations.
Hospitals are Chief End-users
The hospital end-user segment is anticipated to secure the largest market share in the global companion diagnostics market because the fundamental of companion diagnostics and therapy administration is mainly done in hospital settings. Most of the companion diagnostics products are consumed in hospital settings during the treatment of cancer patients at these setups. Hospitals are collaborating with manufacturers to facilitate the patients to leverage the potential of companion diagnostics for enhancing revenue.
For instance, in December 2023, ARUP Laboratories and Medicover collaborated to facilitate the market access of a new companion diagnostic, and a new gene therapy in the European Union (EU). ARUP Laboratories, developed AAV5 DetectCDx, a companion diagnostic in collaboration with BioMarin Pharmaceutical Inc. The test helps in the selection of adult patients suffering from severe hemophilia A who can get treatment with BioMarin’s new gene therapy, ROCTAVIAN (valoctocogene roxaparvovec-rvox). Medicover is the provider of diagnostics and hospital services in the EU and thus contributes largely to the market expansion of AAV5 DetectCDx and ROCTAVIAN in European countries.
North America to be the Dominating Region
Cancer incidence and prevalence are notably higher in North American countries like the United States and Canada, driving higher demand and contributing to the lead of the North America region in the global companion diagnostics market. The demand for companion diagnostics products in the region is anticipated to grow exponentially due to the high number of cancer cases diagnosed, advanced healthcare services, wide adoption and awareness about companion diagnostics, and increasing affordability of healthcare through government support. Additionally, the United States FDA’s significant contribution to product development and regulatory approvals also helps in the market expansion.
For instance, in November 2023, Foundation Medicine Inc. announced the receipt of US FDA approval for FoundationOneCDx as a companion diagnostic solution for AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant). Truqap and Faslodex are already approved by US FDA to treat adult patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, with identified alterations in PIK3CA/AKT1/PTEN genes, after progression on a prior endocrine-based treatment in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.
Future Market Scenario
The future of the global companion diagnostics market holds the development and commercialization of companion diagnostics products that can be used for indications other than oncology such as infectious diseases. Roche’s launched the first infectious disease companion diagnostics tests and cobas omni utility channel in December 2021. Since then, several high-quality products have been in the pipeline and there is notable traction of market players for the development of such products.
For instance, Advanta Genetics is aiming to develop products for infectious disease companion diagnostics using precision metagenomics. Another example from the clinical trial repository indicates three companion diagnostics products of Prometheus Biosciences, Inc., which is a subsidiary of Merck & Co., Inc. The company holds three companion diagnostics products in the pipeline for indications other than cancer such as diffuse cutaneous systemic sclerosis, interstitial lung disease, Crohn's disease, and ulcerative colitis.
Report Scope
“Companion Diagnostics Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global companion diagnostics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031F |
|
Projected Growth Rate |
CAGR of 10.23% between 2024 and 2031F |
|
Revenue Forecast in 2031 |
USD 15.48 billion |
|
Segments Covered |
Product, Technology, Application, End-user |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profile |
Roche Molecular Systems Inc., Dako Inc., Qiagen Ltd., bioMérieux Inc., Ventana Medical Systems Inc., Abbott Molecular Inc., Myriad Genetics Inc., Biogenex Laboratories, Inc., Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmbH |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfill your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In the report, global companion diagnostics market has been segmented into the following categories:
· By Product
o Assay, Kits and Reagents
o Software and Services
· By Technology
o Immunohistochemistry
o Molecular Diagnostics
o In-situ Hybridization
o FISH
o CISH
o Real-time PCR
o Gene Sequencing
· By Application
o Colorectal Cancer
o Breast Cancer
o Lung Cancer
o Melanoma
o Gastric Cancer
o Others
· By End-user
o Pharmaceutical and Biotechnology Companies
o Clinical Research Organizations
o Others
· By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East and Africa
Key Players Landscape and Outlook
The market players are actively involved in the expansion of their market offerings through strategic product development and approvals, mergers and acquisitions, and collaborations with other key players.
In March 2023, QIAGEN N.V. signed up for a strategic partnership with Servier which is a global pharmaceutical organization, to develop a novel companion diagnostic test called TIBSOVO, containing an isocitrate dehydrogenase-1 (IDH1) inhibitor and indicated for the management of the acute myeloid leukemia. Under the Master Collaboration Agreement, QIAGEN is to develop and validate a real-time in-vitro PCR test that can be used for the detection of IDH1 gene mutations in AML patients using their whole blood and bone marrow aspirates. The experienced regulatory teams of QIAGEN will provide support for clinical validation of the companion diagnostic product and its approval in various geographies including the United States, the EU, and Japan.
Key Players Operating in Global Companion Diagnostics Market are:
· Roche Molecular Systems Inc.
· Dako Inc.
· Qiagen Ltd.
· bioMérieux Inc.
· Ventana Medical Systems Inc.
· Abbott Molecular Inc.
· Myriad Genetics Inc.
· Biogenex Laboratories, Inc.
· Thermo Fisher Scientific Inc.
· Leica Biosystems Nussloch GmbH
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global companion diagnostics market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Companion Diagnostics Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. By Product
4.2.1. Assay, Kits and Reagents
4.2.2. Software and Services
4.3. By Technology
4.3.1. Immunohistochemistry
4.3.2. Molecular Diagnostics
4.3.3. In-situ Hybridization
4.3.4. FISH
4.3.5. CISH
4.3.6. Real-time PCR
4.3.7. Gene Sequencing
4.4. By Application
4.4.1. Colorectal Cancer
4.4.2. Breast Cancer
4.4.3. Lung Cancer
4.4.4. Melanoma
4.4.5. Gastric Cancer
4.4.6. Others
4.5. By End-user
4.5.1. Pharmaceutical and Biotechnology Companies
4.5.2. Clinical Research Organizations
4.5.3. Others
4.6. By Region
4.6.1. North America
4.6.2. Europe
4.6.3. Asia-Pacific
4.6.4. South America
4.6.5. Middle East and Africa
4.7. By Company Market Share (%), 2023
5. Global Companion Diagnostics Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1. Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2. By Product
5.1.2.1. Assay, Kits and Reagents
5.1.2.2. Software and Services
5.1.3. By Technology
5.1.3.1. Immunohistochemistry
5.1.3.2. Molecular Diagnostics
5.1.3.3. In-situ Hybridization
5.1.3.4. FISH
5.1.3.5. CISH
5.1.3.6. Real-time PCR
5.1.3.7. Gene Sequencing
5.1.4. By Application
5.1.4.1. Colorectal Cancer
5.1.4.2. Breast Cancer
5.1.4.3. Lung Cancer
5.1.4.4. Melanoma
5.1.4.5. Gastric Cancer
5.1.4.6. Others
5.1.5. By End-user
5.1.5.1. Pharmaceutical and Biotechnology Companies
5.1.5.2. Clinical Research Organizations
5.1.5.3. Others
5.1.6. United States*
5.1.6.1. Market Size & Forecast
5.1.6.1.1. By Value
5.1.6.1.2. By Volume
5.1.6.2. By Product
5.1.6.2.1. Assay, Kits and Reagents
5.1.6.2.2. Software and Services
5.1.6.3. By Technology
5.1.6.3.1. Immunohistochemistry
5.1.6.3.2. Molecular Diagnostics
5.1.6.3.3. In-situ Hybridization
5.1.6.3.4. FISH
5.1.6.3.5. CISH
5.1.6.3.6. Real-time PCR
5.1.6.3.7. Gene Sequencing
5.1.6.4. By Application
5.1.6.4.1. Colorectal Cancer
5.1.6.4.2. Breast Cancer
5.1.6.4.3. Lung Cancer
5.1.6.4.4. Melanoma
5.1.6.4.5. Gastric Cancer
5.1.6.4.6. Others
5.1.6.5. By End-user
5.1.6.5.1. Pharmaceutical and Biotechnology Companies
5.1.6.5.2. Clinical Research Organizations
5.1.6.5.3. Others
5.1.7. Canada
5.1.8. Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. United Kingdom
5.2.5. Russia
5.2.6. Netherlands
5.2.7. Spain
5.2.8. Turkey
5.2.9. Poland
5.3. Asia-Pacific
5.3.1. India
5.3.2. China
5.3.3. Japan
5.3.4. Australia
5.3.5. Vietnam
5.3.6. South Korea
5.3.7. Indonesia
5.3.8. Philippines
5.4. South America
5.4.1. Brazil
5.4.2. Argentina
5.5. Middle East & Africa
5.5.1. Saudi Arabia
5.5.2. UAE
5.5.3. South Africa
6. Market Mapping, 2023
6.1. By Product
6.2. By Technology
6.3. By Application
6.4. By End-user
6.5. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.4.7. Supplier Power
7.4.8. Buyer Power
7.4.9. Substitution Threat
7.4.10. Threat from New Entrant
7.4.11. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Roche Molecular Systems Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Dako Inc.
13.3. Qiagen Ltd.
13.4. bioMérieux Inc.
13.5. Ventana Medical Systems Inc.
13.6. Abbott Molecular Inc.
13.7. Myriad Genetics Inc.
13.8. Biogenex Laboratories, Inc.
13.9. Thermo Fisher Scientific Inc.
13.10. Leica Biosystems Nussloch GmbH
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 3. Global Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 4. Global Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 5. Global Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 6. Global Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 7. Global Companion Diagnostics Market Share (%), By Region, 2017-2031F
Figure 8. North America Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 10. North America Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 11. North America Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 12. North America Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 13. North America Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 14. North America Companion Diagnostics Market Share (%), By Country, 2017-2031F
Figure 15. United States Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 17. United States Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 18. United States Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 19. United States Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 20. United States Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 21. Canada Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 23. Canada Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 24. Canada Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 25. Canada Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 26. Canada Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 27. Mexico Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 29. Mexico Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 30. Mexico Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 31. Mexico Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 32. Mexico Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 35. Europe Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 36. Europe Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 37. Europe Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 38. Europe Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 39. Europe Companion Diagnostics Market Share (%), By Country, 2017-2031F
Figure 40. Germany Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 42. Germany Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 43. Germany Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 44. Germany Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 45. Germany Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 46. France Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 48. France Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 49. France Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 50. France Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 51. France Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 52. Italy Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 54. Italy Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 55. Italy Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 56. Italy Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 57. Italy Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 58. United Kingdom Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 60. United Kingdom Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 61. United Kingdom Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 62. United Kingdom Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 63. United Kingdom Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 64. Russia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 66. Russia Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 67. Russia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 68. Russia Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 69. Russia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 70. Netherlands Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 72. Netherlands Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 73. Netherlands Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 74. Netherlands Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 75. Netherlands Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 76. Spain Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 78. Spain Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 79. Spain Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 80. Spain Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 81. Spain Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 82. Turkey Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 84. Turkey Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 85. Turkey Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 86. Turkey Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 87. Turkey Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 88. Poland Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 90. Poland Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 91. Poland Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 92. Poland Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 93. Poland Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 94. South America Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 96. South America Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 97. South America Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 98. South America Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 99. South America Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 100. South America Companion Diagnostics Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 103. Brazil Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 104. Brazil Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 105. Brazil Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 106. Brazil Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 107. Argentina Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 109. Argentina Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 110. Argentina Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 111. Argentina Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 112. Argentina Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 113. Asia-Pacific Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 115. Asia-Pacific Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 116. Asia-Pacific Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 117. Asia-Pacific Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 118. Asia-Pacific Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 119. Asia-Pacific Companion Diagnostics Market Share (%), By Country, 2017-2031F
Figure 120. India Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 122. India Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 123. India Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 124. India Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 125. India Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 126. China Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 128. China Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 129. China Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 130. China Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 131. China Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 132. Japan Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 134. Japan Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 135. Japan Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 136. Japan Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 137. Japan Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 138. Australia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 140. Australia Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 141. Australia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 142. Australia Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 143. Australia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 144. Vietnam Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 146. Vietnam Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 147. Vietnam Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 148. Vietnam Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 149. Vietnam Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 150. South Korea Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 152. South Korea Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 153. South Korea Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 154. South Korea Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 155. South Korea Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 156. Indonesia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 158. Indonesia Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 159. Indonesia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 160. Indonesia Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 161. Indonesia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 162. Philippines Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 164. Philippines Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 165. Philippines Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 166. Philippines Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 167. Philippines Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 168. Middle East & Africa Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 170. Middle East & Africa Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 171. Middle East & Africa Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 172. Middle East & Africa Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 173. Middle East & Africa Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 174. Middle East & Africa Companion Diagnostics Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 177. Saudi Arabia Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 178. Saudi Arabia Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 179. Saudi Arabia Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 180. Saudi Arabia Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 181. UAE Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 183. UAE Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 184. UAE Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 185. UAE Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 186. UAE Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 187. South Africa Companion Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Companion Diagnostics Market, By Volume, In Billion Units, 2017-2031F
Figure 189. South Africa Companion Diagnostics Market Share (%), By Product, 2017-2031F
Figure 190. South Africa Companion Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 191. South Africa Companion Diagnostics Market Share (%), By Application, 2017-2031F
Figure 192. South Africa Companion Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
Who are the key players operating in global companion diagnostics market?
What are the regions covered in the final report for global companion diagnostics market?
What are the major drivers influencing the growth of global companion diagnostics market?
What is the market size and growth rate of global companion diagnostics market?
See Related Reports
Global Industrial PPE Market Assessment, Opportunities and Forecast, 2017-2031F
Rising awareness about hazardous workplace environments, government stringent policies and compliances, new PPE technology, and usage of advanced material is anticipated to add value to the global industrial PPE market growth trajectory.....Read More
Published on
June 2024
4,500
Global Mouthwash Market Assessment, Opportunities and Forecast, 2017-2031F
Global mouthwash market is anticipated to grow due to various therapeutic benefits such as relieving pain, promote healing of various dental issues such as oral sores and ulcers, and consumers’ increasing awareness of the importance of maintenance of....Read More
Published on
June 2024
4,500
Global Rehabilitation Equipment Market Assessment, Opportunities and Forecast, 2017-2031F
Rehabilitation equipment is a vital tool for improving patient outcomes, increasing the speed of healing, and getting people back to their best possible functioning levels. Muscle strength, voluntary movements, and balance are all enhanced by physica....Read More
Published on
June 2024
4,500
Global Orthodontic Supplies Market Assessment, Opportunities and Forecast, 2017-2031F
The orthodontic supplies market is expected to grow because of increasing developments in technology, rising awareness about aesthetically pleasing looks, rising prevalence of dental disorders, and huge investments made by industry giants in market.....Read More
Published on
June 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
